کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2106679 1083600 2007 14 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Management of symptomatic, untreated chronic lymphocytic leukemia
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Management of symptomatic, untreated chronic lymphocytic leukemia
چکیده انگلیسی

SummaryFludarabine-based regimens have become an increasingly popular first-line approach for symptomatic patients with chronic lymphocytic leukemia. Compared with chlorambucil, fludarabine alone or in combination with cyclophosphamide or rituximab yields higher response rates, higher complete remission rates, and more durable progression-free survival. Immunotherapy and chemoimmunotherapy also have the potential to increase the depth of remission as assessed by flow cytometry or molecular techniques. An overall survival advantage with any one particular regimen has not yet been demonstrated. Progress with fludarabine-based regimens, monoclonal antibodies, chemoimmunotherapy, and high-dose therapy for previously untreated patients is reviewed. Fluorescent in situ hybridization and immunoglobulin variable heavy-chain sequencing now permit more individualized risk assessment. Examples of possible treatment algorithms based on risk category are explored. How to tailor treatment based on these newer prognostic factors remains a central, as yet unanswered management question.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Blood Reviews - Volume 21, Issue 3, May 2007, Pages 143–156
نویسندگان
, ,